Treating Relapsed CLL

CME

Answering Key Questions in the Optimal Treatment for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: December 23, 2024

Expiration: June 22, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In which of the following settings is pirtobrutinib approved by the FDA for patients with CLL?